8-K: Decoy Therapeutics Holds Annual Meeting, Elects Directors
Annual Meeting Results
Decoy Therapeutics Inc. held its 2026 Annual Meeting of Stockholders, re-electing directors, approving executive compensation, and ratifying auditor appointment.
Summary
- Decoy Therapeutics Inc. convened its 2026 Annual Meeting of Stockholders on July 14, 2026.
- A quorum was established with 42.4% of outstanding shares present or represented by proxy.
- Stockholders re-elected three Class II directors: Patricia Gauthier, Jonathan Lieber, and Frederick E. Pierce.
- The compensation of named executive officers was approved via a non-binding advisory vote.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it reports on routine annual meeting outcomes without significant new strategic information or financial performance data.
Positives
- Successful re-election of all three Class II director nominees.
- Approval of executive compensation through a non-binding advisory vote.
- Ratification of Ernst & Young LLP as the independent auditor for the upcoming fiscal year.
- Quorum achieved, indicating sufficient shareholder participation.
Future Outlook
The filing does not contain specific forward-looking statements or guidance beyond the ratification of the auditor for the fiscal year ending December 31, 2026.
Industry Context
StockSavvy.ai notes that annual meetings are standard corporate events for publicly traded companies to fulfill governance requirements and engage with shareholders on key decisions.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Class II Director | N/A | Patricia Gauthier | July 14, 2026 | Election at Annual Meeting |
| Class II Director | N/A | Jonathan Lieber | July 14, 2026 | Election at Annual Meeting |
| Class II Director | N/A | Frederick E. Pierce | July 14, 2026 | Election at Annual Meeting |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Election | Election of three Class II directors to serve until the 2029 annual meeting. | July 14, 2026 | Maintains board continuity and fulfills governance requirements. |
| Executive Compensation Approval | Non-binding advisory vote to approve the compensation of named executive officers. | July 14, 2026 | Provides shareholder feedback on executive pay practices. |
| Auditor Ratification | Ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal year ending December 31, 2026. | July 14, 2026 | Confirms auditor independence and oversight. |
Stakeholder Impact
- Shareholders: Exercised voting rights on director elections, executive compensation, and auditor ratification, influencing corporate governance.
- Management: Received advisory approval for compensation, impacting morale and retention.
- Auditors: Ernst & Young LLP's appointment was ratified, confirming their role in financial oversight.
Next Steps
- The newly elected Class II directors will serve until the 2029 annual meeting.
- Ernst & Young LLP will serve as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Key Dates
| Date | Description |
|---|---|
| May 22, 2026 | Record date for the 2026 Annual Meeting of Stockholders. |
| July 14, 2026 | Date of the 2026 Annual Meeting of Stockholders. |
| July 15, 2026 | Date of the Form 8-K filing. |
| December 31, 2026 | Fiscal year end for which Ernst & Young LLP was appointed as independent auditor. |
| 2029 | Term end for newly elected Class II directors. |
Keywords
Decoy Therapeutics, Annual Meeting, Stockholder Vote, Director Election, Executive Compensation, Auditor Ratification, Corporate Governance, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.